Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

Subcutaneous allergen immunotherapy (SCIT) for aeroallergens is covered for patients with allergic rhinitis, allergic conjunctivitis, allergic asthma, or dust-mite–associated atopic dermatitis (AD) when there are symptoms on natural exposure and demonstrable specific IgE, and after failure/intolerance of appropriate pharmacotherapy/environmental control (≥28 days; ≥90 days for AD). An initial maintenance course of 3–5 years is recommended with evaluations every 6–12 months; exclusions include SLIT, SCIT during pregnancy, absence of specific IgE, food sensitivities, and non-aeroallergens (e.g., venom) under this LCD.

"Allergic rhinitis and/or allergic conjunctivitis (seasonal, perennial, or both) when the patient has symptoms on natural exposure and demonstrable specific IgE and at least one of: poor response to..."

Sign up to see full coverage criteria, indications, and limitations.